<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102705">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02156960</url>
  </required_header>
  <id_info>
    <org_study_id>Deno-PTH2365</org_study_id>
    <nct_id>NCT02156960</nct_id>
  </id_info>
  <brief_title>Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shinshu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shinshu University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has not been well known about the changes of bone metabolic markers, bone mineral density
      and other bone-related markers after teriparatide and/or denosumab treatment in Japanese
      osteoporotic patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes of bone mineral density</measure>
    <time_frame>every 4-6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Bone mineral density will be examined every 4-6 months to evaluate the suitability of the drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of bone turnover markers</measure>
    <time_frame>every 3-6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Bone turnover markers will be examined every 3-6 months to evaluate the suitability of the drug.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab and/or teriparatide treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab and/or teriparatide treatment in osteoporotic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab treatment in osteoporotic patients</intervention_name>
    <description>To examine the effectiveness of denosumab in osteoporotic patients</description>
    <arm_group_label>Denosumab and/or teriparatide treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide treatment in osteoporotic patients</intervention_name>
    <description>To examine the effectiveness of teriparatide in osteoporotic patients</description>
    <arm_group_label>Denosumab and/or teriparatide treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab and teriparatide treatment in osteoporotic patients</intervention_name>
    <description>To examine the effectiveness of denosumab and teriparatide in osteoporotic patients</description>
    <arm_group_label>Denosumab and/or teriparatide treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoporotic patients

        Exclusion Criteria:

          -  Kidney disease,  parathyroid disease, congenital bone metabolic disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yukio Nakamura, MD, PhD</last_name>
    <phone>+81-263-37-2659</phone>
    <email>yxn14@aol.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yukio Nakamura</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>3908621</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukio Nakamura, MD, PhD</last_name>
      <phone>+81-263-37-2659</phone>
      <email>yxn14@aol.jp</email>
    </contact>
    <investigator>
      <last_name>Yukio Nakamura, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shinshu University</investigator_affiliation>
    <investigator_full_name>Yukio Nakamura</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
